throbber
UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`SAMSUNG ELECTRONICS CO., LTD.,
`SAMSUNG ELECTRONICS AMERICA, INC.,
`Petitioners,
`
`v.
`
`NANOCO TECHNOLOGIES LTD.,
`Patent Owner.
`
`Case No. IPR2021-00186
`U.S. Patent No. 8,524,365
`
`PATENT OWNER’S PRELIMINARY RESPONSE
`PURSUANT TO 37 C.F.R. § 42.107(a)
`
`

`

`Case No. IPR2021-00186
`U.S. Patent No. 8,524,365
`
`3.
`
`4.
`
`5.
`
`6.
`
`I.
`II.
`
`TABLE OF CONTENTS
`INTRODUCTION AND SUMMARY OF ARGUMENT .............................. 1
`THE BOARD SHOULD DENY INSTITUTION UNDER 35 U.S.C. §
`314(a) ............................................................................................................... 4
`A.
`All of the factors considered under Fintiv support a
`discretionary denial in order to promote the most efficient and
`fair adjudication of the parties’ dispute. ................................................ 6
`1.
`The district court denied Petitioner’s motion for a stay ............. 6
`2.
`The district court’s trial date will precede the Board’s
`projected statutory deadline for a final written decision
`by approximately seven months.................................................. 7
`The parties have invested significant resources in the
`Parallel Proceeding ................................................................... 10
`There is substantial overlap between the issues raised in
`the petition and in the Parallel Proceeding ............................... 12
`The Petitioner and the Defendant in the Parallel
`Proceeding are the same party .................................................. 14
`Additional circumstances weigh in favor of the Board’s
`exercise of discretion ................................................................ 14
`III. OVERVIEW OF QUANTUM DOTS ........................................................... 15
`IV. OVERVIEW OF NANOPARTICLE SYNTHESIS METHODS ................. 21
`A.
`Nanorods and Nanowires .................................................................... 23
`1.
`The Vapor-Liquid-Solid Method .............................................. 23
`2.
`The Solution-Liquid-Solid Method .......................................... 25
`Quantum Dots ...................................................................................... 27
`1.
`The Solid-State Method ............................................................ 27
`
`B.
`
`i
`
`

`

`Case No. IPR2021-00186
`U.S. Patent No. 8,524,365
`
`The Hot-Injection Method ........................................................ 28
`2.
`The Heat-Up Method ................................................................ 30
`3.
`The Molecular Cluster-Assisted Method .................................. 32
`4.
`THE CHALLENGED ’365 PATENT ........................................................... 33
`V.
`VI. CLAIM CONSTRUCTION .......................................................................... 35
`A. Molecular Cluster Compound ............................................................. 35
`VII. THE PETITION SHOULD BE DENIED BECAUSE IT DOES NOT
`ESTABLISH THE REQUIRED REASONABLE LIKELIHOOD OF
`SUCCESS OF PROVING CHALLENGED CLAIMS
`UNPATENTABLE ........................................................................................ 37
`A.
`The Proposed Grounds 1-4: Banin ...................................................... 37
`1.
`Banin Does Not Disclose a Molecular Cluster Compound ...... 37
`2.
`Adding Herron to Banin Cannot Render Obvious Any of
`the Challenged ’365 Patent Claims ........................................... 42
`a.
`Banin and Herron (Ground 3) ......................................... 43
`Proposed Ground 5: Zaban in View of Farneth/Yu ............................ 48
`1.
`A Person of Skill in the Art Would Not Combine Zaban’s
`Group III-V Quantum Dot Process with Farneth’s Group
`II-VI Solid-state Intermediate ................................................... 48
`a.
`A Person of Skill in the Art Would Not Swap
`Zaban’s Zinc Acetate for Farneth’s 10-Zinc
`Precursor Because It Would Change the Nature of
`Zaban’s Quantum Dots ................................................... 49
`Petitioner’s purported motivation does not come
`from any of the references .............................................. 52
`Proposed Grounds 6 and 7: Lucey in View of Ahrenkiel ................... 54
`
`B.
`
`b.
`
`C.
`
`ii
`
`

`

`1.
`
`Case No. IPR2021-00186
`U.S. Patent No. 8,524,365
`
`2.
`
`Lucey Uses the Hot-Injection Method to make Quantum
`Dots, While Ahrenkiel Uses the SLS Method to Make
`Quantum Rods ........................................................................... 54
`Even Replacing Lucey’s Precursor with Ahrenkiel’s
`Multiple Precursors Would Not Practice the Claims of
`the ’365 Patent Because Both of Ahrenkiel’s Precursors
`Provide the Ions to Be Incorporated into the
`Semiconductor Core .................................................................. 55
`Lucey’s Expressly Teaches Away from Ahrenkiel’s
`Chlorine-Based Precursors ........................................................ 57
`There Is No Motivation to Combine Lucey and
`Ahrenkiel, and No Reasonable Expectation of Success ........... 58
`VIII. CONCLUSION .............................................................................................. 61
`
`3.
`
`4.
`
`iii
`
`

`

`Case No. IPR2021-00186
`U.S. Patent No. 8,524,365
`
`TABLE OF AUTHORITIES
`
` Page(s)
`
`Cases
`Apple Inc., v. Fintiv, Inc.,
`IPR2020-00019, Paper 11 (PTAB March 20, 2020) ...................................passim
`Apple Inc. v. Fintiv,
`IPR2020-00019, Paper 15 (PTAB May 13, 2020) ......................................... 7, 10
`Apple Inc. v. Seven Networks, LLC,
`IPR2020-00235, Paper 10 (PTAB July 28, 2020) ................................................ 8
`In re Am. Acad. of Sci. Tech Ctr.,
`367 F.3d 1359 (Fed. Cir. 2004) .......................................................................... 45
`In re Fine,
`837 F.2d 1071 (Fed. Cir. 1988) .......................................................................... 53
`In re Fritch,
`972 F.2d 1260 (Fed. Cir. 1992) .......................................................................... 53
`In re NuVasive, Inc.,
`842 F.3d 1376 (Fed. Cir. 2016) .......................................................................... 53
`Kinetic Concepts, Inc. v. Smith Nephew, Inc.,
`688 F.3d 1342 (Fed. Cir. 2012) .......................................................................... 42
`Nanoco Technologies Ltd. v. Samsung Electronics Co., Ltd.,
`No. 2:20-cv-00038 (E.D. Tex.) ......................................................................... 5, 6
`NHK Spring Co., Ltd. v. Intri-Plex Techs., Inc.,
`IPR2018-00752, Paper 8, 20 (PTAB Sept. 12, 2018)................................. 5, 7, 15
`Otsuka Pharmaceutical Co., Ltd. v. Sandoz, Inc.,
`678 F.3d 1280 (Fed. Cir. 2012) .......................................................................... 47
`Phillips v. AWH Corp.,
`415 F.3d 1303 (Fed. Cir. 2005) (en banc) .......................................................... 35
`
`iv
`
`

`

`Case No. IPR2021-00186
`U.S. Patent No. 8,524,365
`
`Samsung Electronics Co., Ltd. et al v. Red Rock Analytics, LLC,
`IPR2018-00555, Paper 16 (PTAB Aug. 30, 2018) ............................................. 47
`Sand Revolution II, LLC v. Cont’l Intermodal Grp.-Trucking LLC,
`IPR2019-01393, Paper 24 (PTAB June 16, 2020) ............................................... 8
`Sanofi-Synthelabo v. Apotex, Inc.,
`550 F.3d 1075 (Fed. Cir. 2008) .......................................................................... 53
`Snap, Inc. v. SRK Technology LLC,
`IPR2020-00820, Paper 15 (PTAB Oct. 21, 2020) ................................................ 5
`Sotera Wireless, Inc. v. Masimo Corp.,
`IPR2020-01018, Paper 12 (PTAB Dec. 1, 2020) ........................................... 5, 13
`Statutes
`35 U.S.C. § 314(a) ....................................................................................... 4, 7, 8, 15
`35 U.S.C. § 315 ........................................................................................................ 13
`Other Authorities
`37 CFR § 42.100(b) ................................................................................................. 35
`37 CFR § 42.100(c) .................................................................................................... 7
`37 CFR § 42.24(d) ................................................................................................... 62
`37 CFR § 42.65 ........................................................................................................ 45
`MPEP § 2143.01 ...................................................................................................... 47
`
`v
`
`

`

`Case No. IPR2021-00186
`U.S. Patent No. 8,524,365
`
`Exhibit
`2001
`2002
`2003
`2004
`
`2005
`
`2006
`
`2007
`
`2008
`
`2009
`
`2010
`
`2011
`
`2012
`
`2013
`
`2014
`
`TABLE OF EXHIBITS
`
`Description
`Declaration of Michael C. Newman
`Declaration of Thomas H. Wintner
`Declaration of Matthew S. Galica
`Periodic table of the elements, Encyclopaedia Britannica, Inc.,
`available at https://www.britannica.com/science/periodic-table (last
`visited Feb. 18, 2021)
`Samsung Global Newsroom. Quantum Dot Artisan: Dr. Eunjoo Jang,
`Samsung Fellow, November 30, 2017
`ACS Energy Lett. 2020, 5, 1316-1327. “Environmentally Friendly
`InP-Based Quantum Dots for Efficient Wide Color Gamut Displays”
`Wang, F., Dong, A. and Buhro, W.E., Solution–liquid–solid
`synthesis, properties, and applications of one-dimensional colloidal
`semiconductor nanorods and nanowires. Chemical
`Reviews, 116(18):10888-10933 (2016).
`Wang, F., et al., Solution− liquid− solid growth of semiconductor
`nanowires. Inorganic chemistry, 45(19):7511-7521 (2006).
`Madkour, L.H., Synthesis Methods For 2D Nanostructured
`Materials, Nanoparticles (NPs), Nanotubes (NTs) and Nanowires
`(NWs). In Nanoelectronic Materials (pp. 393-456). Springer, Cham.
`(2019)
`Mushonga, P., et al., Indium phosphide-based semiconductor
`nanocrystals and their applications. Journal of Nanomaterials, 1-11
`(2012).
`Luo, H., Understanding and controlling defects in quantum confined
`semiconductor systems, Doctoral dissertation, Kansas State
`University (2016).
`Sinatra, L., et al. Methods of synthesizing monodisperse colloidal
`quantum dots. Material Matters, 12:3-7 (2017)
`Pu, Y., et al., Colloidal synthesis of semiconductor quantum dots
`toward large-scale production: a review. Industrial & Engineering
`Chemistry Research, 57(6):1790-1802 (2018).
`Rao, C. N. R.; Gopalakrishnan, J., Chapter 3: Preparative Strategies
`from New Directions in Solid State Chemistry; Cambridge University
`Press: Cambridge, UK (1986).
`
`vi
`
`

`

`Case No. IPR2021-00186
`U.S. Patent No. 8,524,365
`
`Exhibit
`2015
`
`2016
`
`2017
`
`2018
`
`2019
`
`2020
`
`2021
`
`2022
`
`2023
`
`2024
`
`2025
`
`2026
`
`Description
`Glossary of Common Wafer Related Terms, BYU Electrical &
`Computer Engineering Integrated Microfabrication Lab, definition of
`degenerate semiconductor, available at
`https://cleanroom.byu.edu/ew_glossary (last visited Feb. 19, 2021)
`October 22, 2006 email between Eunjoo Jang and Nigel Pickett Re:
`Cd free quantum dots
`Weare, W.W., Reed, S.M., Warner, M.G. and Hutchison, J.E.,
`Improved synthesis of small (d core≈ 1.5 nm) phosphine-stabilized
`gold nanoparticles. Journal of the American Chemical
`Society, 122(51):12890-12891 (2000).
`Samsung’s Motion to Stay Pending Inter Partes Review of the
`Asserted Patents in Case 2:20-cv-00038-JRG, filed on November 30,
`2020
`Order denying Samsung’s Motion to Stay Pending Inter Partes
`Review in Case 2:20-cv-00038-JRG, filed on January 8, 2021
`Standing Order Regarding the Novel Coronavirus (Covid-19) for the
`Eastern District of Texas Marshall Division, signed March 3, 2020
`Standing Order Regarding Pretrial Procedures In Civil Cases
`Assigned to Chief District Judge Rodney Gilstrap During the
`Present Covid-19 Pandemic, signed April 20, 2020
`Samsung’s Preliminary Invalidity Contentions and Disclosures
`Pursuant To Patent Rules 3-3 and 3-4 (served November 9, 2020)
`Merriam-Webster Dictionary, online edition. Definition of
`“Halogen”, available at https://www.merriam-
`webster.com/dictionary/halogen (last visited Feb. 23, 2021)
`Illustrated Glossary of Organic Chemistry, UCLA. Illustration of
`Halide, available at
`http://www.chem.ucla.edu/~harding/IGOC/H/halide.html (last
`visitied Feb. 23, 2021)
`Mortvinova, N.E., Vinokurov, A.A., Lebedev, O.I., Kuznetsova,
`T.A., and Dorofeev, S.G., Addition of Zn during the phosphine-based
`synthesis of indium phospide quantum dots:doping and surface
`passivation, Beilstein J Nanotechnol. 2015; 6: 1237-1246.
`Samsung’s Proposed Claim Constructions (served December 11,
`2020)
`
`vii
`
`

`

`Case No. IPR2021-00186
`U.S. Patent No. 8,524,365
`
`Exhibit
`2027
`
`2028
`2029
`
`Description
`He, Z., Yang, Y., Liu, J.W. and Yu, S.H., Emerging tellurium
`nanostructures: controllable synthesis and their
`applications. Chemical Society Reviews, 46(10): 2732-2753 (2017)
`INTENTIONALLY LEFT BLANK
`Makkar, M. and Viswanatha, R., Frontier challenges in doping
`quantum dots: synthesis and characterization. Rsc
`Advances, 8(39):22103-22112 (2018).
`
`viii
`
`

`

`Case No. IPR2021-00186
`U.S. Patent No. 8,524,365
`
`I.
`
`INTRODUCTION AND SUMMARY OF ARGUMENT
`For at least the following independent reasons, Samsung Electronics Co., Ltd.
`
`and Samsung Electronics America, Inc.’s (collectively, “Samsung” or “Petitioner”)
`
`Petition should be denied institution.
`
`First, the Board should deny institution of the Petition in view of its
`
`precedential NHK and Fintiv decisions because Nanoco Technologies Ltd. (“Patent
`
`Owner” or “Nanoco”) and Petitioner are scheduled to try the validity of the
`
`challenged patent in a district court jury trial seven months before the deadline of a
`
`Final Written Decision in this requested inter partes review. All six Fintiv factors
`
`weigh in favor denying institution.
`
`Second, Samsung’s Petition fails to establish the required likelihood that it
`
`will prove that any challenged claim of Nanoco’s U.S. Patent No. 8,524,365 (Ex.
`
`1001) (the “’365 patent”) is unpatentable.
`
`The ’365 patent claims are directed to quantum dots and methods of producing
`
`quantum dots. Quantum dots are man-made semiconductor nanoparticles that can
`
`emit light at very particular wavelengths. Quantum dots were traditionally made of
`
`compounds such as cadmium selenide (CdSe). But cadmium is highly toxic, so there
`
`was a push to create cadmium-free quantum dots out of material such as indium
`
`phosphide (InP). And while it is difficult to make any quantum dot in commercially
`
`viable quantities, these problems are compounded when cadmium is not used. The
`
`1
`
`

`

`Case No. IPR2021-00186
`U.S. Patent No. 8,524,365
`
`claims of the ’365 patent are directed toward commercial quantities of quantum dots,
`
`including indium phosphide quantum dots, which are a viable cadmium-free option
`
`as a result.
`
`The claimed nanoparticles and ways of preparing them involve a core
`
`semiconductor material disposed on a molecular cluster compound where the core
`
`material contains elements that are not in the molecular cluster compound. Ex. 1001
`
`at 10:9-13. A molecular cluster compound is a small cluster of 3 or more metal or
`
`nonmetal atoms and their associated ligands of sufficiently well-defined chemical
`
`structure such that all molecules of the cluster compound possess the same relative
`
`molecular mass. Id. at 5:19-25. Thus, for example, molecular clusters are identical
`
`to one another in the same way that one H2O molecule is identical to another H2O.
`
`Id. at 5:25-28.
`
`Petitioner’s proposed Grounds 1-4 rely on Banin as a primary reference.
`
`Banin does not disclose a molecular cluster compound. Banin’s alleged “clusters”
`
`are simply melted gold droplets that have up to a 25% variation in their composition,
`
`and contain impurities. These metal droplets lack the sufficiently well-defined
`
`chemical structure of a molecular cluster compound. See Section VII.A infra.
`
`Moreover, Petitioner’s secondary reference, Herron (Ground 3), discloses bulk metal
`
`intermediates that show no evidence of being able to liquefy (i.e., melt) and function
`
`as a catalyst in Banin’s Solution-Liquid-Solid (“SLS”) method for growing
`
`2
`
`

`

`Case No. IPR2021-00186
`U.S. Patent No. 8,524,365
`
`nanorods. And Treadway which is added to Banin in Ground 4 for the purposes of
`
`accounting for shells with ternary and quaternary semiconductor materials, does not
`
`remedy Banin’s deficiencies.
`
`Petitioner’s Ground 5 relies on Zaban as a primary reference. While Zaban
`
`makes indium phosphide quantum dots, Petitioner does not even allege that Zaban
`
`uses any “clusters” at all. And the cluster disclosed by the secondary reference,
`
`Farneth, is an intermediate isolated during a solid state reaction for making bulk
`
`metal zinc sulfide (ZnS). This bulk metal zinc sulfide process is very different from
`
`the process for growing indium phosphide quantum dots discussed in Zaban.
`
`Moreover, using Farneth’s cluster in combination with Zaban, would not work.
`
`Zaban very deliberately adds a single zinc atom to each of its quantum dots.
`
`Applying Farneth’s zinc-based clusters would result in up to 10 times the amount of
`
`zinc in Zaban’s quantum dots, fundamentally changing their properties. And Yu, has
`
`little to do with either Farneth or Zaban and thus is a singularly poor choice for
`
`Petitioner’s proposed combination. See Section VII.B infra.
`
`The Petition’s Grounds 6 and 7 are weaker still. These Grounds rely upon
`
`Lucey as a primary reference. Petitioner merely waves its hands at the critical claim
`
`element requiring a “core semiconductor material that comprises one or more
`
`elements not comprised within the molecular cluster compound” as required by all
`
`claims in the ’365 patent. Lucey teaches the exact opposite of this. The alleged
`
`3
`
`

`

`Case No. IPR2021-00186
`U.S. Patent No. 8,524,365
`
`“cluster compound” in Lucey is a precursor that contribute atoms to the
`
`semiconductor core. Therefore the “cluster compound” and “core semiconductor”
`
`have the same elements. Same with the Ahrenkiel secondary reference. Both of
`
`Ahrenkiel’s precursors provide indium phosphide to a growing indium phosphide
`
`semiconductor core. That both Lucey and Ahrenkiel provide exactly the same
`
`elements comprised in the core, not different ones. What’s more, Lucey actually
`
`teaches away from Ahrenkiel which uses precursors containing chlorine atoms in
`
`them—expressly what Lucey states should not be used in a precursor. See Section
`
`VII.C infra.
`
`Because Petitioner’s grounds fail to disclose critical claim elements, and there
`
`is no reason to combine Banin with Herron or Treadway, Zaban with Farneth/Yu or
`
`Lucey with Ahrenkiel/Treadway other than Petitioner’s improper hindsight effort to
`
`assemble portions of divergent references to create something that might
`
`approximate the invention of the ’365 patent, there is no reasonable likelihood of
`
`success that Petitioner will prove any of the challenged claims are unpatentable, and
`
`the Board should thus deny institution.
`
`II.
`
`THE BOARD SHOULD DENY INSTITUTION UNDER 35 U.S.C. §
`314(a)
`The ’365 patent is owned by Nanoco, a leading pioneer in the development of
`
`nanomaterials and quantum dots for use in TV displays. Nanoco sued Petitioner for
`
`4
`
`

`

`Case No. IPR2021-00186
`U.S. Patent No. 8,524,365
`
`infringement of the ’365 patent in the District Court for the Eastern District of Texas,
`
`captioned Nanoco Technologies Ltd. v. Samsung Electronics Co., Ltd., No. 2:20-cv-
`
`00038 (E.D. Tex.), filed February 14, 2020 (“Parallel Proceeding”). Petition at 66.
`
`In that Parallel Proceeding, Petitioner has raised a plethora of invalidity defenses,
`
`including all of the ones presented in the Petition. Ex. 2022 at 184-199. As Petitioner
`
`concedes, the district court has scheduled a trial to begin in October 2021, more than
`
`seven months before any final written decision deadline will become due in the
`
`requested IPR. Petition at 62. In light of the overlapping invalidity issues presented,
`
`as well as the resources required by both parties in the Parallel Proceeding, a
`
`discretionary denial of the Petition under the Board’s controlling precedent is
`
`appropriate. See, e.g., Apple Inc., v. Fintiv, Inc., IPR2020-00019, Paper 11 (PTAB
`
`Mar. 20, 2020) (precedential) (“Fintiv”); NHK Spring Co., Ltd. v. Intri-Plex Techs.,
`
`Inc., IPR2018-00752, Paper 8 at 20 (PTAB Sept. 12, 2018).1
`
`1 See also Sotera Wireless, Inc. v. Masimo Corp., IPR2020-01018, Paper 12 (PTAB
`
`Dec. 1, 2020) (precedential); Snap, Inc. v. SRK Technology LLC, IPR2020-00820,
`
`Paper 15 (PTAB Oct. 21, 2020) (precedential).
`
`5
`
`

`

`Case No. IPR2021-00186
`U.S. Patent No. 8,524,365
`
`A.
`
`All of the factors considered under Fintiv support a discretionary
`denial in order to promote the most efficient and fair adjudication
`of the parties’ dispute.
`1.
`The district court denied Petitioner’s motion for a stay
`The first factor favors denying the Petition in light of the earlier-scheduled
`
`district court trial and the district court’s denial of a motion to stay. As noted in
`
`Patent Owner’s Mandatory Notice, both Petitioner and the Patent Owner are
`
`involved in the Parallel Proceeding, filed over a year ago, involving the same patent:
`
`Nanoco Technologies Ltd. v. Samsung Electronics Co., Ltd., No. 2:20-cv-00038
`
`(E.D. Tex.). See Petition at 71. Petitioner discusses Fintiv factor 1 by contending
`
`that the Board “finding the Challenged Claim unpatentable will relieve the district
`
`court of the need to continue with the District Court case,” and that Petitioner would
`
`move to stay the district court proceeding to further promote “simplification.” Id. at
`
`67. Petitioner brought a motion to stay and similarly argued to the district court that
`
`“[a] stay would save precious judicial and party resources.” Ex. 2018 at 6.
`
`Petitioner’s arguments about efficiency and simplification are greatly
`
`diminished by the unnecessary duplication and overlap between the grounds
`
`presented in the Petition and the all-inclusive grounds in the invalidity contentions
`
`served in the Parallel Proceeding. See Section II.A.4, infra (discussing the fourth
`
`Fintiv factor). Moreover, since the district court promptly denied Petitioner’s motion
`
`6
`
`

`

`Case No. IPR2021-00186
`U.S. Patent No. 8,524,365
`
`for a stay, this factor weighs in favor of the Board exercising discretion to deny the
`
`Petition. Ex. 2019 at 3.
`
`2.
`
`The district court’s trial date will precede the Board’s
`projected statutory deadline for a final written decision by
`approximately seven months
`Factor two weighs in favor of denying institution, and Petitioner does not
`
`argue otherwise. Petition at 68 (“[T]his factor is neutral or weighs at most only
`
`slightly in favor of PO.”) (emphasis added). Indeed, as Petitioner acknowledges, the
`
`district court has scheduled jury selection for October 4, 2021. Petition at 67; Ex.
`
`1018. This is more than seven months earlier than the projected statutory deadline
`
`for a final written decision of the requested IPR, which would issue sometime in
`
`May 2022. See Ex. 1018; IPR2021-00186 at Paper 4; 35 U.S.C. § 314(a); 37 CFR §
`
`42.100(c).
`
`This factor is nowhere close to being “neutral.” The circumstances here are
`
`even more compelling than those in Fintiv, where the trial was scheduled to begin
`
`only two months before the final written decision was due, or those of NHK, where
`
`the Board determined that an inter partes review that would not conclude until
`
`almost six months after a district court trial “would be an inefficient use of Board
`
`resources.” See Apple Inc. v. Fintiv, Inc., IPR2020-00019, Paper 15 at 13 (PTAB
`
`May 13, 2020); NHK, IPR2018-00752, Paper 8 at 20. The circumstances of this
`
`proceeding are also the exact opposite of what Fintiv identified as those in which
`
`7
`
`

`

`Case No. IPR2021-00186
`U.S. Patent No. 8,524,365
`
`“the Board may be less likely to deny institution under 35 U.S.C. § 314(a) based on
`
`district court trial timing,” i.e., where “the district court has set a date after the
`
`Board’s deadline to issue a final written decision.” Fintiv at 3 (emphasis in original).
`
`Despite acknowledging that this factor is not favorable to them, Petitioner
`
`attempts to cast doubt on the anticipated trial date due to the Covid-19 pandemic.
`
`While short-citing to non-precedential Board institution decisions, Petitioner
`
`represents that the Board has recognized that Fintiv factor 2 is diminished by
`
`uncertainties due to the ongoing pandemic. Petition at 67-68 (citing Apple Inc. v.
`
`Seven Networks, LLC, IPR2020-00235, Paper 10 at 8-9 (PTAB July 28, 2020) and
`
`Sand Revolution II, LLC v. Cont’l Intermodal Grp.-Trucking LLC, IPR2019-01393,
`
`Paper 24 at 9-10 (PTAB June 16, 2020)). Petitioner’s cited cases are inapposite. In
`
`both, the Board relied heavily on the fact that the parties had previously agreed to
`
`extend scheduled dates, including the trial date. See Sand Revolution, IPR2019-
`
`01393, Paper 24 at 9-10 (relying in particular on “the number of times the parties
`
`have jointly moved for and the district court agreed to extend the scheduling order
`
`dates.”); see also Apple, IPR2020-00235, Paper 10 at 9 (noting the parties’
`
`agreements to move the trial date while determining that Fintiv factor 2 still weighs
`
`in favor of Patent Owner).
`
`Here, there have been no extensions of the trial schedule in the Parallel
`
`Proceeding, nor has Judge Gilstrap indicated that he has any intention of moving the
`
`8
`
`

`

`Case No. IPR2021-00186
`U.S. Patent No. 8,524,365
`
`trial date until after the deadline for a final written decision. In addition to rejecting
`
`Petitioner’s motion to stay in the Parallel Proceeding, Judge Gilstrap issued a
`
`standing order on March 3, 2020 that counsels the parties to come together to
`
`minimize the impact of any potential issues related to Covid-19, including exploring
`
`any “appropriate means to conduct the hearing, trial, or deposition,” such as by
`
`videoconference. Ex. 2020; see also Ex. 2021 (Standing Order Regarding Pretrial
`
`Procedures). Notably, in Google LLC, Samsung Electronics Co., Ltd., and Samsung
`
`Electronics America, Inc. v. AGIS Software Development LLC, which also involved
`
`a parallel proceeding before Judge Gilstrap, the petitioners similarly argued that the
`
`trial date was uncertain, but the Board rejected the argument:
`
`On the record before us at this time, the only persuasive facts that we
`have regarding the proximity of the court’s trial date to the Board’s
`projected statutory deadline for a final written decision is an Order by
`the District Court that sets trial for April 5, 2021, which will require
`“good cause” to be changed, and our projected statutory deadline,
`which would be toward the end of November 2021. While we
`appreciate that the trial date is susceptible to change if and when the
`District Court determines good cause exists to do so, we decline to
`speculate whether such a contingency will occur. Instead, we must base
`our evaluation on the existing facts supported by the evidence of record.
`This factor, therefore, significantly favors the exercise of discretionary
`denial.
`
`9
`
`

`

`Case No. IPR2021-00186
`U.S. Patent No. 8,524,365
`
`IPR2020-00870, Paper 16 at 11 (PTAB Nov. 25, 2020) (denying institution)
`
`(emphasis in original).2
`
`The outcome should be the same here. The seven month gap between the start
`
`of trial and a final written decision from the Board should control in the absence of
`
`any evidence demonstrating that the trial will be postponed. See Apple, IPR2020-
`
`00019, Paper 15 at 13 (“We generally take courts’ trial schedules at face value absent
`
`some strong evidence to the contrary.”) (emphasis added). Fintiv factor 3 weighs in
`
`favor of the Board exercising its discretion to deny the Petition.
`
`3.
`
`The parties have invested significant resources in the
`Parallel Proceeding
`The Parallel Proceeding is already well underway. The parties began
`
`producing documents and serving their infringement and invalidity contentions3 last
`
`year. Ex. 1018. The parties have already substantially completed discovery. Id. Well
`
`before the Board decides whether or not to institute, the parties will have filed and
`
`2 The Board offered the same analysis while denying institution of the other IPR
`
`petitions brought by the same petitioners in IPR2020-00871, Paper 16 at 11 (PTAB
`
`Nov. 25, 2020), IPR2020-00872, Paper 16 at 9-10 (PTAB Nov. 25, 2020), and
`
`IPR2020-00873, Paper 16 at 9-10 (PTAB Nov. 25, 2020).
`
`3
`
`10
`
`

`

`Case No. IPR2021-00186
`U.S. Patent No. 8,524,365
`
`exchanged claim construction briefs and conducted the Markman hearing, which is
`
`scheduled for March 26, 2021. Id. Moreover, by the time the Board issues its
`
`decision on whether to institute the requested IPR, the parties will have served initial
`
`expert exports, fact discovery will have closed, and dispositive motions will be a
`
`month out. Id. This will require immense time and effort for both sides. Petitioner’s
`
`argument that “[t]he parties and district court will have invested limited resources in
`
`the District Court case” prior to the deadline for the Board’s institution decision,
`
`(Petition at 68), simply does not hold water.
`
`Petitioner applauds its purported efforts to file the Petition “promptly,”
`
`Petition at 68-69, it was served concurrently with Petitioner’s invalidity contetnions
`
`in the Parallel Proceeding. Petitioner’s statement that “Here, Petitioner filed its
`
`Petition before serving its invalidity contentions,” is untrue or even if technically
`
`true, highly misleading. See Petition at 69. The Petition was filed and served on the
`
`same day that Petitioner served its Invalidity Contentions in the Parallel Proceeding.
`
`Compare Petition at Certificate of Service with Ex. 2022 at 204 (Certificate of
`
`Service). Given how far along the Parallel Proceeding will be by the time of an
`
`institution decision and the resources both Parties will have to expend before that
`
`time, this factor strongly favors denial.
`
`11
`
`

`

`Case No. IPR2021-00186
`U.S. Patent No. 8,524,365
`
`4.
`
`There is substantial overlap between the issues raised in the
`petition and in the Parallel Proceeding
`Factor four also weighs in favor of denying the Petition. Petitioner does not
`
`deny the nearly complete overlap between the invalidity issues raised in the Petition
`
`and in the Parallel Proceeding. Petition at 69. All of the grounds raised in the Petition
`
`are being raised, or are reserved to be raised, in the Parallel Proceeding. Petitioner
`
`notes that it has represented that “if this IPR proceeding is instituted, [Petitioners]
`
`will not pursue invalidity on the same grounds or grounds based on the same primary
`
`references in the District Court case.” Petition at 69. But this is an empty promise.
`
`Petitioner’s representation that it will forgo pursuing the proposed grounds,
`
`or grounds based on the same primary references if the Board institutes a trial, is
`
`meaningless given that the primary references (Banin, Zabin and Lucey) identified
`
`in the Petition are just two of many references that Petitioner contends, through its
`
`district court invalidity contentions, either anticipate or render obvious the ’365
`
`Patent claims. Ex. 2022 at 184-199. Petitioner’s kitchen-sink approach to invalidity
`
`in the district court demonstrates that Petitioner intends to litigate validity issues in
`
`both forums, no matter what. See, e.g., Google and Samsung, IPR2020-00870, Paper
`
`16 at 15-16 (noting that such ambiguously worded “conditional stipulations” that
`
`limit any waiver to the conditional grounds in the petition do not alleviates the
`
`concerns of potential inefficiencies and conflicting decisions).
`
`12
`
`

`

`Case No. IPR2021-00186
`U.S. Patent No. 8,524,365
`
`Petitioner’s proposal gives up far less than the statutory estoppel to which
`
`Petitioner would already be subject after a final written decision. Compare Petition
`
`at 69 (representing that Petitioners will not pursue invalidity on the same grounds
`
`or grounds based on the same primary references in the District Court case”) with
`
`35 U.S.C. § 315 (barring a Petitioner from asserting in district court proceeding that
`
`a claim “is invalid on any ground that the petitioner raised or reasonably could have
`
`raised during that inter partes review”); see also Ex. 1022. Petitioner’s carefully
`
`worded stipulation also falls far short of the standard created by the precedential
`
`Sotera decision, where the Board cited and relied upon a stipulation from the
`
`Petitioner that

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket